title: Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab.
authors.forename: Ilaria
authors.initials: I
authors.lastname: Puxeddu
authors.forename: Lucia
authors.initials: L
authors.lastname: Giori
authors.forename: Valeria
authors.initials: V
authors.lastname: Rocchi
authors.forename: Laura
authors.initials: L
authors.lastname: Bazzichi
authors.forename: Stefano
authors.initials: S
authors.lastname: Bombardieri
authors.forename: Antonio
authors.initials: A
authors.lastname: Tavoni
authors.forename: Paola
authors.initials: P
authors.lastname: Migliorini
authors.forename: Isabella
authors.initials: I
authors.lastname: Del Corso
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D007558:Italy; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014581:Urticaria / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D007073:Immunoglobulin E; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept